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Background Accumulating evidence implicates insufficient oxidative capacity in
the development of type 2 diabetes. This notion has not been well
tested in large, population-based studies.
Methods To test this hypothesis, we assessed the cross-sectional associ-
ation of plasma lactate, an indicator of the gap between
oxidative capacity and energy expenditure, with type 2 diabetes in
1709 older adults not taking metformin, who were participants
in the Atherosclerosis Risk in Communities (ARIC) Carotid MRI
Study.
Results The prevalence of type 2 diabetes rose across lactate quartiles
(11, 14, 20 and 30%; P for trend <0.0001). Following adjustment
for demographic factors, physical activity, body mass index and
waist circumference, the relative odds of type 2 diabetes across
lactate quartiles were 0.98 [95% confidence interval (CI)
0.59–1.64], 1.64 (95% CI 1.03–2.64) and 2.23 (95% CI 1.38–3.59),
respectively. Furthermore, lactate was associated with higher fast-
ing glucose among non-diabetic adults.
Conclusions Plasma lactate was strongly associated with type 2 diabetes in older
adults. Plasma lactate deserves greater attention in studies of oxi-
dative capacity and diabetes risk.
Keywords Diabetes mellitus, type 2, lactic acid, epidemiology, oxidative phos-
phorylation, glycolysis, insulin resistance
Introduction
Accumulating evidence implicates insufficient oxida-
tive capacity in the development of insulin resistance
and type 2 diabetes.
1–20 This evidence includes the
association of insulin resistance and type 2 diabetes
with maternally inherited forms of diabetes,
1,2
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1647increased glycolysis in muscle,
3–5 decreased mitochon-
drial size and density,
6–10 decreased oxidative gene
expression,
10–14 decreased oxidative phosphoryl-
ation
14–18 and decreased aerobic capacity.
13,19,20
However, clinical research on oxidative capacity as a
mediator the physiological effects of obesity has been
limited by the absence of a marker of oxidative cap-
acity for use in populations.
Blood lactate is a measure of the gap between
energy expenditure and oxidative capacity. Lactate is
used clinically to indicate energy imbalance associated
with vigorous exercise, hypoxia and ischaemia.
21,22
Prior work also suggests that lactate is elevated
among obese, insulin-resistant subjects
23,24 and de-
creases with weight loss.
25 These studies were limited
by small, highly selected samples, however. One pro-
spective study further suggested that serum lactate
may be an independent risk factor for the develop-
ment of type 2 diabetes.
26 This study included only
white men.
Given lactate’s association with insulin resistance
and type 2 diabetes in earlier studies and the accu-
mulating evidence linking oxidative capacity to insu-
lin resistance, we hypothesized that decreased
oxidative capacity, as assessed by higher levels of
plasma lactate, is associated with type 2 diabetes.
We therefore examined the cross-sectional association
of plasma lactate, obesity and type 2 diabetes in the
Atherosclerosis Risk in Communities (ARIC) Carotid
MRI (CAR–MRI) study, a community-based cohort of
2066 older white and African American adults.
Material and methods
Study population and design
The ARIC study was initiated in 1987 to study the
development and progression of cardiovascular dis-
ease in African American and white men and
women (n¼15792), aged 45–64 years, selected from
four communities in the USA (Forsyth County, NC;
Jackson, MS; suburban Minneapolis, MN and
Washington County, MD).
27 The ARIC CAR–MRI
study, described herein, enrolled participants from
the ARIC cohort, now aged 60–84 years. The study
was designed to investigate the genomic, metabolic
and cellular correlates of carotid artery atherosclerotic
plaque characterized using high-resolution contrast-
enhanced magnetic resonance imaging (MRI). The
study was approved by the institutional review
boards of the participating institutions, and all par-
ticipants gave their informed consent.
ARIC participants were selected using a stratified
sampling design that oversampled those subjects
with the thickest carotid artery intima-media thick-
ness (IMT) at the most recent ultrasound examin-
ation (visits 3 or 4, 1993–98). Site-specific carotid
artery IMT cut-points were adjusted to achieve
targeted group sizes of  1200 with thick walls
(e.g. high IMT) and  800 participants without high
IMT. The cut-points ranged from 1.00 to 1.28mm
(69th to 73rd percentile) to allow for an approximate-
ly equal distribution of participants across field cen-
tres. The cut points were chosen in order to maximize
the number of individuals with detectable plaque,
while still being able to make generalizable inferences
to the ARIC base population. A total of 4307 persons
were invited to participate. Of these, 1404 refused,
837 were ineligible and 2066 participated (48%). The
final ARIC CAR–MRI sample included 1250 high-IMT
individuals and 816 individuals randomly sampled
from the remainder of the IMT distribution.
The measurement of lactate was approved by the
ARIC Steering Committee as an ARIC ancillary
study. Non-fasting individuals and individuals with
missing variables of interest (e.g. lactate, diabetes
and potential confounders) were excluded from the
final analysis. Since metformin increases blood lactate
levels, an additional 143 subjects with type 2 diabetes
(26%) were excluded if they were taking metformin
during the 4weeks prior to the CAR–MRI examin-
ation.
28 After exclusions, the final analysis sample
included 1709 CAR–MRI participants.
Baseline variables and data collection
The core examination procedures are identical to
those previously established by ARIC.
27 Briefly, a
90-min examination was performed in the morning
after a 12-h fast. After informed consent, trained
technicians performed anthropometry measurements
and obtained urine and blood samples. Blood samples
were collected in 10-ml potassium–EDTA (lavender
top) tubes (Becton, Dickinson and Company).
Following each blood draw, blood was iced immedi-
ately and kept between 0 and 88C prior to centrifuga-
tion (3000g for 20min at 48C). Within 30min of the
blood draw, plasma was aliquoted and stored at –708C
at the field centres. Frozen samples where then
shipped by Federal Express Priority Overnight mail
to the ARIC central laboratories for long-term storage
and analysis.
Exposure
Plasma lactate was measured using an enzymatic re-
action to convert lactate to pyruvate using a Roche
Hitachi 911 auto-analyzer.
29 The Roche analyzer uses
the enzyme lactate oxidase (LOD) to convert L-lactate
to pyruvate and hydrogen peroxide (H2O2):
L-Lactate þ O2
LOD
() Pyruvate þ H2O2
The hydrogen peroxide subsequently reacts with
peroxidase to generate a coloured dye. This is the
preferred method because it has better reagent stabil-
ity than previous enzymatic methods.
29
In order to assess the reliability of the lactate meas-
urements, we performed within-visit and repeat-visit
assessments of plasma lactate. The quality control
1648 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYanalysis of blind replicate samples in 117 pairs
demonstrated a within-visit coefficient of reliability
of 0.93 with a coefficient of variation of 9.2%. The
quality-control analysis of samples drawn from 61 in-
dividuals on separate days demonstrated a day-to-day
coefficient of repeatability of 0.55 with a coefficient of
variation across the two visits of 24.7%. The mean
difference between the repeat and study measurement
was small (mean¼–0.11mg/dl) and not significantly
different from zero [95% confidence interval (CI) –
0.82, 0.60mg/dl]. Furthermore, no systematic bias
was detected (test for the proportion of positive dif-
ferences¼50%, P¼0.694).
Outcome
Type 2 diabetes was defined as a fasting glucose
57.0mmol/l (5126mg/dl; reported a minimum of
8h of fasting prior to visit), a self-reported physician
diagnosis, or diabetes treatment in the 4 weeks prior
to the clinic visit.
Covariates
Other variables of interest included age, race, sex,
ARIC field centre, triglycerides, high-density lipopro-
tien (HDL) and low-density lipoprotien (LDL) choles-
terol, diabetes medication use, body mass index
(BMI), waist circumference, prevalent coronary heart
disease, smoking status (never, former, current) and
leisure-time physical activity. Details have been previ-
ously described for measurement of plasma lipids,
30
fasting glucose
31 and determination of BMI (kg/m
2).
32
Physical activity was assessed using the Baecke phys-
ical activity questionnaire.
33 To ascertain medication
use, participants were asked to bring containers of
current medications to the visit. Fasting insulin was
not assessed during this visit.
Statistical analyses
Data are expressed as means and 95% CIs unless
otherwise specified. All statistical analyses incorpo-
rated the stratified random sampling design, for
estimation, testing and CIs, using Stata 9.2.
34
Sampling weights were based on the probability of
being selected from each field centre based upon the
high-IMT status of each participant. The sampling
weight among high-IMT subjects was approximately
equal to 1 for all field centres. The sampling weights
for individuals in the remainder of the IMT distribu-
tion varied according to field centre, ranging from 3.9
to 6.1. The advantage of the stratified sampling design
is that it allowed for oversampling of high-IMT sub-
jects, while maintaining balanced proportions of sub-
jects from each centre, enabling us to make
generalizable inferences to the ARIC base population;
however, the precision of the estimates is decreased
relative to analysis of the entire study population.
Characteristics of subjects participating in the ARIC
CAR–MRI study were first compared across lactate
quartiles. To assess for linear trends across quartiles,
accounting for the sampling distribution and non-
linearity in the lactate distribution, survey-weighted
logistic regression and survey-weighted linear regres-
sion were utilized, treating the variable of interest as
the dependent variable and the median lactate value
for each quartile as a continuous independent
variable. Multivariate survey-weighted logistic regres-
sion analysis was then conducted to assess the
cross-sectional association of type 2 diabetes with lac-
tate quartile. Initial models adjusted for ethnicity,
gender, age, high-IMT status, ARIC field centre and
leisure-time physical activity. BMI and waist circum-
ference were added to the model to assess the impact
of adiposity. The final model further adjusted for tri-
glycerides. Subsequent analyses were conducted
among non-diabetics to assess the association of lac-
tate with fasting glucose.
Results
Distribution of lactate
Plasma lactate was distributed approximately
log-normally with a median value of 7.2mg/dl
[inter-quartile range (IQR) 5.9–9.0; Figure 1].
Clinically, plasma lactate is routinely used to assess
poor tissue oxygenation associated with ischaemic
bowel and circulatory collapse. In the presence of
these disorders, plasma lactate commonly rises to
values 436mg/dl. By contrast, most ARIC CAR–MRI
participants (95.7%) fell well within the normal range
(4.5–19.8mg/dl).
35 The distribution of plasma lactate
did not differ by age or gender, but did vary by eth-
nicity [whites 7.1mg/dl (IQR 5.9–8.7); African
Americans 7.7mg/dl (IQR 6.5–9.9), P<0.0001].
Figure 1 Probability of type 2 diabetes across the
distribution of blood lactate among 1749 older adults. Bars
represent the distribution of lactate. The solid line denotes
the predicted probability of type 2 diabetes (right axis); 95%
CIs are shaded in grey; Triangles (bottom) represent the
individual cases of type 2 diabetes
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lactate quartile
Overall, 56% of ARIC CAR–MRI participants were
women, 19% were African American and the mean
age was 70.4 years (range 60–84). Higher lactate
was associated with both BMI (P<0.0001) and
waist circumference (P<0.0001) (Table 1). In the
first quartile of lactate, 29% of subjects were obese
(mean BMI 27.9kg/m
2), whereas 48% of subjects in
the fourth quartile were obese (mean BMI 30.4kg/m
2;
Ptrend <0.0001). Higher lactate also was associated
with higher triglycerides, lower HDL and a higher
prevalence of type 2 diabetes.
Association of lactate with prevalent
type 2 diabetes
The relationship between lactate and type 2 diabetes
is illustrated in Figure 1. A strong, linear and graded
association between lactate quartile and prevalent
type 2 diabetes was seen, increasing from 12% in
the first quartile to 30% in the fourth quartile
(Ptrend<0.0001; Table 2). In the unadjusted logistic
model, the fourth quartile of lactate was associated
with a 3.25-fold increase in the odds of prevalent
type 2 diabetes when compared with the first quartile
(95% CI 2.05–5.14). Following adjustment for
age, gender, ethnicity, field centre, high-IMT status,
prevalent coronary heart disease, smoking status,
leisure-time activity, BMI and waist circumference
(Model 3), the odds ratio estimates in the second,
third and fourth quartiles were somewhat attenuated,
but the linear trend remained highly significant
(Ptrend<0.0001): 0.98 (95% CI 0.59–1.64), 1.64 (95%
CI 1.03–2.64) and 2.23 (95% CI 1.38–3.59). The linear
trend across lactate quartiles remained significant
(P¼0.002) after further adjustment for triglycerides.
Adjustment for use of anti-hypertensive medications
and HMG-CoA reductase inhibitors attenuated the as-
sociation only slightly (data not shown).
Additional analyses were stratified by ethnicity to
assess potential differences in the distribution of lac-
tate by race. Among whites, a strong, linear and
graded association between lactate quartile and preva-
lent type 2 diabetes was seen. No association was
seen between lactate quartile and prevalent type 2
diabetes among African Americans. This difference
by ethnicity was largely due to a higher prevalence
of type 2 diabetes in the first quartile of lactate
(33.1%) relative to the second quartile (17.1%)
among African Americans.
Analysis of lactate among non-diabetic
adults
The trends by lactate quartile among non-diabetic
adults paralleled those seen in the full cohort
(Table 3). BMI, waist circumference and triglycerides
all increased with higher lactate levels. In particular,
the triglyceride/HDL ratio increased in a graded fash-
ion by lactate quartile, from 1.97 in the first quartile
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1650 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYto 3.35 in the fourth quartile (Ptrend<0.0001).
Similarly, the frequency of having a triglyceride/HDL
ratio of 53, a marker of insulin resistance, increased
from 27 to 57% across lactate quartiles
(Ptrend <0.0001). The association between lactate
quartile and glucose, triglyeride and triglyceride/HDL
ratios remained after adjustment for BMI and waist
circumference (Table 3, last column). Furthermore,
the association was minimally attenuated in the
model adjusting for demographic factors, high IMT,
BMI and fasting glucose level (Figure 2). Unlike the
heterogeneity seen in the association of lactate with
prevalent type 2 diabetes across ethnic groups, the
association of lactate with triglyceride/HDL ratio
among non-diabetic individuals was strong and
linear for African Americans and whites. Parallel ana-
lyses with lactate and fasting glucose showed that
lactate levels were lowest among subjects with
normal fasting glucose levels, intermediate
among subjects with impaired fasting glucose
(100–125mg/dl), and highest among subjects with
type 2 diabetes in both whites and African
Americans (data not shown).
Discussion
Our results show that lactate’s association with preva-
lent type 2 diabetes is strong, graded and independ-
ent. The graded association occurred across the
normal clinical range of lactate values. The strength
of the association was robust and independent of
measures of adiposity. Among non-diabetics, plasma
lactate was associated with higher fasting glucose, tri-
glycerides and triglyceride–HDL ratio, a marker of in-
sulin resistance.
36,37
Our results are consistent with previous studies re-
porting an association between lactate, adiposity and
type 2 diabetes. Small clinical studies have shown
that lactate is higher among obese subjects
23,24 and
decreases with weight loss.
25 Work by Chen and col-
leagues demonstrated that lactate is low in lean
subjects, higher in non-diabetic obese subjects and
still higher in obese diabetics.
38 In two small, cross-
sectional studies, lactate was correlated with insulin
resistance independent of obesity.
39,40 In a longitudin-
al analysis of Swedish men, elevated serum lactate
was associated with a 2.4-fold higher incidence of
type 2 diabetes.
26 The association was attenuated
after adjusting for BMI and other factors, however,
and lactate was not included in the final model
based on a step-wise regression analysis.
26 Taken to-
gether, these studies suggest that lactate is associated
with both obesity and its downstream complications
including insulin resistance and type 2 diabetes.
Although compelling, these findings were from
small clinical studies or of limited generalizability.
Our study is the largest population-based study
to date investigating the association of lactate and
type 2 diabetes. Strengths of our study include the
large community-based sample of white and African
American men and women, and extensive data on
potential confounders.
Adipose tissue is responsible for a large portion of
the lactate produced in obesity.
25,41 Among obese sub-
jects, decreased blood flow to adipose tissue leads to
local hypoxia and increased lactate production.
42
Furthermore, adipocyte production of lactate increases
as adipocyte size increases,
24,41,43 approaching the dif-
fusion limit of oxygen.
42 Therefore, decreased oxygen
availability in adipocytes may drive a major portion of
the excess lactate production associated with obesity.
There is also evidence that hypoxia drives adipocyto-
kine dysregulation
42 and decreased insulin signal-
ling
44 in adipocytes from obese individuals. In this
study, lactate’s association with type 2 diabetes was
independent of BMI, however, suggesting that lactate
is not solely a marker of adiposity. Alternatively,
blood lactate may indicate the activity of adipose
tissue, or its degree of hypoxia and decreased oxida-
tive capacity, which is not captured by BMI and other
measures of adiposity.
Oxidative capacity may also be decreased in
insulin-resistant skeletal muscle. The evidence
Table 2 Odds of prevalent type 2 diabetes by plasma lactate quartile among 1709 older adults in the ARIC CAR–MRI study
a
Model
b
Lactate quartile
units
Diabetes prevalence 123 4
<5.9 12 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
5.9–7.2 14 1.23 (0.76–2.01) 1.10 (0.67–1.79) 0.98 (0.59–1.64) 0.94 (0.56–1.57)
7.3–9.1 19 1.84 (1.15–2.95) 1.78 (1.12–2.84) 1.64 (1.03–2.64) 1.47 (0.91–2.36)
59.2 30 3.25 (2.05–5.14) 2.74 (1.71–4.37) 2.23 (1.38–3.59) 1.82 (1.12–2.95)
P (trend)
c <0.0001 <0.0001 <0.0001 <0.0001 0.002
aExcluding type 2 diabetics taking metformin.
bModel 1 is the unadjusted model. Model 2 adjusts for age, gender, ethnicity, high-IMT status, ARIC field centre, prevalent
coronary heart disease, smoking status and leisure time activity. Model 3 additionally adjusts for BMI and waist circumference.
Model 4 further adjusts for triglycerides.
cPtrend was calculated using survey-weighted logistic regression, treating the median lactate values by quartile as a continuous
independent variable.
ASSOCIATION OF BLOOD LACTATE WITH TYPE 2 DIABETES 1651supporting this notion includes the association of in-
sulin resistance and type 2 diabetes with increased
glycolysis in muscle,
3–5 decreased mitochondrial size
and density,
6–10 decreased oxidative gene expres-
sion,
10–14 decreased oxidative phosphorylation
14–18
and decreased aerobic capacity.
13,19,20 The decrease
in oxidative capacity may account for the markedly
altered lactate metabolism in insulin-resistant
muscle, where lactate concentration is increased and
the lactate–pyruvate interconversion rates are
enhanced as much as 3- to 4-fold.
45,46 The expression
of the lactate transporter monocarboxylate transport
protein 1 (MCT1) is altered as well.
46 In skeletal
muscle, lactate functions to shuttle oxidative precur-
sors from glycolytic fibres to oxidative fibers.
47 MCT4
facilitates lactate’s transfer out of glycolytic fibres and
MCT1 facilitates lactate’s transfer into oxidative fibres
where it is oxidized.
48 The expression of MCT1 is
markedly decreased in insulin-resistant muscle.
46
Although the reason for the decreased expression is
unknown, these findings are consistent with a
decreased capacity to oxidize exogenous lactate in oxi-
dative fibres, leading to decreased expression of
MCT1. Taken together, the association of blood lactate
with type 2 diabetes may result from a global decrease
in oxidative capacity which leads to altered lactate
metabolism in insulin-resistant muscle and increased
lactate release from adipose tissue.
Lactate’s association with type 2 diabetes may also
be causal. DiGirolamo and colleagues have argued
that the elevated lactate associated with obesity may
be at least partially responsible for insulin resist-
ance.
24 Elevated lactate may promote hepatic gluco-
neogenesis and interfere with glucose uptake in
muscle by substituting for glucose utilization.
49 The
evidence in support of this notion is mixed; lactate
infusion decreases glucose oxidation, for example,
but does not increase the rate of glucose production.
50
Lactate’s potential causal role in insulin resistance
needs further study.
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Figure 2 Association of triglyceride–HDL ratio with plasma
lactate quartile among non-diabetics. Beta coefficients are
adjusted for age, sex, high-IMT status, field centre, BMI and
fasting glucose. Lactate quartiles are represented by the
median lactate value within each quartile
1652 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYSeveral limitations of our study deserve mention.
First, because our study was cross-sectional, it was
not possible to determine whether elevated lactate is
a cause or consequence of type 2 diabetes. Therefore,
we cannot rule out the possibility that type 2 diabetes
leads to higher lactate levels. However, lactate was
associated with markers of fasting glucose among
non-diabetics, suggesting that lactate elevation is
not just a consequence of type 2 diabetes. A specific
mechanism potentially linking diabetes with elevated
lactate is poor tissue oxygenation due to cardiovascu-
lar disease in diabetic participants. Adjustment for
prevalent coronary heart disease, however, attenuated
the association between lactate and prevalent diabetes
only slightly. Second, lactate can be artificially
elevated because of ongoing glycolysis following the
blood draw. This effect was minimized through the
rapid processing and cooling of blood samples and
would have biased our results toward the null; it is
highly unlikely that glycolysis in the samples would
produce the large and graded associations here
described. Third, the day-to-day repeatability of rest-
ing blood lactate is moderate, reflecting known diur-
nal variation in lactate levels and sensitivity of lactate
to changes in the metabolic state. Despite this vari-
ation, lactate was strongly associated with type 2 dia-
betes. Finally, we recognize that lactate is only an
indirect indicator of oxidative capacity.
Our results show that plasma lactate is strongly
associated with prevalent type 2 diabetes among
non-diabetics. The association of lactate with type 2
diabetes supports the potential role of decreased oxi-
dative capacity in the aetiology of insulin resistance.
Plasma lactate deserves greater attention in epidemio-
logic and physiologic studies of oxidative capacity and
diabetes risk. Further work must be carried out to
reassess the prospective association of plasma lactate
and type 2 diabetes in a modern cohort. If confirmed,
blood lactate measurement could be used as a marker
of oxidative capacity in clinical and population
studies.
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KEY MESSAGES
  Insufficient oxidative capacity, also referred to as mitochondrial dysfunction, may play a role in the
development of type 2 diabetes.
  Blood lactate, a commonly used marker of decreased tissue oxygenation in circulatory collapse and of
oxidative capacity during exercise, may be a good indicator of oxidative capacity at rest.
  In a large population-based sample of older adults, blood lactate’s association with prevalent type 2
diabetes was strong, graded and independent of measures of obesity. The graded association occurred
across the normal range of lactate values and supports the notion that decreased oxidative capacity is
related to type 2 diabetes.
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